This Death Row Inmate’s Blood-Filled Tumors Could Make His Execution Especially Cruel and Unusual

Russell Bucklew suffers from a rare disease.

Missouri's death chamberJames A. Finley/AP

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Missouri death row inmate Russell Bucklew is scheduled to die on Tuesday. But Bucklew suffers from a rare medical condition, and his lawyers say the execution drug that will be used could come with gruesome consequences and constitute cruel and unusual punishment.

For nearly all his life, Bucklew has been afflicted with cavernous hemangioma, a rare disease that causes tumors to form in his face, head, neck, and throat. Prison staff intend to use pentobarbital, a sedative, to execute him, but this could cause his tumors to burst. Cheryl Pilate, one of Bucklew’s lawyers told the Associated Press on Monday, he would likely experience “a gruesome execution with choking and gagging on blood and the infliction of excruciating pain.” 

Bucklew, who is 49 years old, has been on death row for more than 20 years for the 1996 murder of Michael Sanders in Cape Giradeau, Missouri. Sanders was the new boyfriend of Bucklew’s former girlfriend Stephanie Ray. Bucklew shot Sanders in front of his children, Ray, and her children and then kidnapped Ray and took her to a secluded area. After raping her, he drove her to the St. Louis area as a hostage where a high-speed chase and shootout with a state trooper ensued. Bucklew was arrested and held in the Cape Girardeau County jail but escaped a few months later in June by hiding in a trash can that was taken out of the prison. While on the run, he went to the home of Ray’s mother and attacked her with a hammer, but she survived. Two days later, Bucklew was apprehended and jailed. In 1997, he was convicted of kidnap, rape, and murder, and sentenced to death.

Missouri first attempted to execute Bucklew in May 2014, but the US Supreme Court granted a stay in order to allow Bucklew’s claims that his execution would be painful to work its way through the lower courts. Bucklew’s lawyers argued that given his illness, he could not be humanely executed, and this cruel and unusual punishment would be a violation of the Eighth Amendment. In Glossip v. Gross, the US Supreme Court said that when the Eighth Amendment is used to challenge a method of execution a “reasonable alternative” must be proposed by the inmate. 

In the 2014 appeal, Bucklew’s lawyers suggested that the state use nitrogen gas to execute him. (The state of Oklahoma recently proposed it as an alternative to lethal injection.) According to court documents, Dr. Joel Zivot, a professor of surgery and anesthesiology at Emory University said that “substantial risk” exists that Bucklew will “suffer from extreme or excruciating pain.” But last June, a federal judge ruled that because Bucklew could not actually show that death by nitrogen would reduce the risk of suffering, his execution should proceed.  

Missouri uses a one-drug protocol in its executions in which death row inmates are injected with a large dose of the sedative pentobarbital. According to a Buzzfeed News report, the state’s drug supplier is a pharmacy with a history of selling contaminated drugs, and anti-death penalty advocates argue that contaminated pentobarbital would also cause a painful death for Bucklew.

Last week, in the appeal Bucklew’s lawyers filed with the US Supreme Court, they asked for the court to spare his life and painted a grim picture of what could happen during the execution. “As he struggles to breathe through the execution procedure,” they wrote, “Bucklew’s throat tumor will likely rupture…filling his mouth and airway with blood, causing him to choke and cough on his own blood.”

WE CAME UP SHORT.

We just wrapped up a shorter-than-normal, urgent-as-ever fundraising drive and we came up about $45,000 short of our $300,000 goal.

That means we're going to have upwards of $350,000, maybe more, to raise in online donations between now and June 30, when our fiscal year ends and we have to get to break-even. And even though there's zero cushion to miss the mark, we won't be all that in your face about our fundraising again until June.

So we urgently need this specific ask, what you're reading right now, to start bringing in more donations than it ever has. The reality, for these next few months and next few years, is that we have to start finding ways to grow our online supporter base in a big way—and we're optimistic we can keep making real headway by being real with you about this.

Because the bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

payment methods

WE CAME UP SHORT.

We just wrapped up a shorter-than-normal, urgent-as-ever fundraising drive and we came up about $45,000 short of our $300,000 goal.

That means we're going to have upwards of $350,000, maybe more, to raise in online donations between now and June 30, when our fiscal year ends and we have to get to break-even. And even though there's zero cushion to miss the mark, we won't be all that in your face about our fundraising again until June.

So we urgently need this specific ask, what you're reading right now, to start bringing in more donations than it ever has. The reality, for these next few months and next few years, is that we have to start finding ways to grow our online supporter base in a big way—and we're optimistic we can keep making real headway by being real with you about this.

Because the bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate